Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMUS001 in metastatic pancreatic cancer
ISRCTN75002153Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Sep 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of paclitaxel, oxaliplatin, folinic acid, fluorouracil and gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Progression-free survival. Started Sep 2017; status: completed.
02
Drugs
paclitaxeloxaliplatinfolinic acidfluorouracilgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN75002153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN75002153.